Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.

MLA

Russo, Vincenzo, et al. “Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.” Clinical Therapeutics, vol. 41, no. 12, Dec. 2019, pp. 2549–57. EBSCOhost, https://doi.org/10.1016/j.clinthera.2019.10.008.

APA

Russo, V., Carbone, A., Attena, E., Rago, A., Mazzone, C., Proietti, R., Parisi, V., Scotti, A., Nigro, G., Golino, P., & D’Onofrio, A. (2019). Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves. Clinical Therapeutics, 41(12), 2549–2557. https://doi.org/10.1016/j.clinthera.2019.10.008

Chicago

Russo, Vincenzo, Andreina Carbone, Emilio Attena, Anna Rago, Carmine Mazzone, Riccardo Proietti, Valentina Parisi, et al. 2019. “Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.” Clinical Therapeutics 41 (12): 2549–57. doi:10.1016/j.clinthera.2019.10.008.